Literature DB >> 18731688

TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives.

N A Bercel.   

Abstract

A comparison of nicotinic acid, a non-narcotic analgesic and a series of injectable and oral ergot preparations tested by various methods in treating 40 patients with typical migraine indicate that ergot alkaloids are far superior in producing symptomatic relief.A comparison of ergotamine tartrate, dihydroergotamine (DHE-45) and dihydroergocornine (DHO-180) indicated that ergotamine tartrate is the most effective and perhaps the most toxic, DHE-45 is slightly less effective and considerably less toxic, and that DHO-180 is the least effective but also the least toxic. When given orally, these alkaloids were about half as effective as when given by injection. EC-110 (ergotamine nitrate with caffeine) was the most effective.DHO-180 in liquid form, given daily for one month, had a marked preventive effect on migraine attacks.

Entities:  

Year:  1950        PMID: 18731688      PMCID: PMC1520523     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  4 in total

1.  Buccal absorption of ergotamine.

Authors:  J M Sutherland; W D Hooper; M J Eadie; J H Tyrer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-10       Impact factor: 10.154

2.  Effect of caffeine on intestinal absorption of ergotamine in man.

Authors:  R Schmidt; A Fanchamps
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

3.  Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase.

Authors:  Mark Andrew White; Wei Lin; Xiaodong Cheng
Journal:  bioRxiv       Date:  2020-08-10

4.  Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase.

Authors:  Mark Andrew White; Wei Lin; Xiaodong Cheng
Journal:  J Phys Chem Lett       Date:  2020-10-14       Impact factor: 6.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.